| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.YGYNO.2015.11.003 |
| P698 | PubMed publication ID | 26586415 |
| P2093 | author name string | Robert S Mannel | |
| Kathleen N Moore | |||
| P2860 | cites work | Intratumor heterogeneity: evolution through space and time | Q24598678 |
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet | Q26799864 | ||
| Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity | Q26992272 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 | ||
| Combined vemurafenib and cobimetinib in BRAF-mutated melanoma | Q27853076 | ||
| Improved overall survival in melanoma with combined dabrafenib and trametinib | Q27853091 | ||
| Integrated genomic analyses of ovarian carcinoma | Q27860518 | ||
| Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 | ||
| Integrated genomic characterization of endometrial carcinoma | Q28289962 | ||
| Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia | Q29614280 | ||
| Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial | Q29614756 | ||
| HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients | Q33305210 | ||
| Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial | Q34551403 | ||
| Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. | Q34587751 | ||
| Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma | Q34664981 | ||
| Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. | Q34743609 | ||
| American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy | Q34935716 | ||
| Adjuvant trastuzumab in HER2-positive breast cancer | Q35710898 | ||
| The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research | Q35892395 | ||
| A review of phase II trial designs for initial marker validation. | Q37188715 | ||
| Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix | Q37678092 | ||
| Ovarian cancer: targeting the untargetable | Q38214258 | ||
| National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network | Q38214265 | ||
| Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial | Q38581287 | ||
| HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. | Q39098938 | ||
| Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group | Q73520711 | ||
| NCI-MATCH trial pushes cancer umbrella trial paradigm | Q95416330 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 161-166 | |
| P577 | publication date | 2015-11-13 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | Is the NCI MATCH trial a match for gynecologic oncology? | |
| P478 | volume | 140 |
| Q89591831 | An overview of precision oncology basket and umbrella trials for clinicians |
| Q53071118 | Clinical trial methodology in rare gynecologic tumor research: Strategies for success. |
| Q99408621 | Comparison of Annotation Services for Next-Generation Sequencing in a Large-Scale Precision Oncology Program |
| Q47322951 | Definitions and statistical properties of master protocols for personalized medicine in oncology |
| Q54969621 | Precision Medicine Requires Precision Laboratories. |
| Q89975407 | Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer |
| Q92112381 | Reporting of master protocols towards a standardized approach: A systematic review |
| Q39126105 | Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples |
| Q36849660 | The potential for liquid biopsies in the precision medical treatment of breast cancer |
| Q50059524 | Who are the long-term survivors of high grade serous ovarian cancer? |
Search more.